BOT Shares Botanix Pharmaceuticals Limited
ASX · ASXLast in our picks 2026-10-23 — not in the current list; analysis below is from that screen
Dermatology commercialization and regulatory execution provide a clearer path toward value creation.
Signal breakdown
- ▸Commercial launch progress and regulatory milestones support improving momentum.
- ▾Below 50-day MA (-33.11%)
- ▾Near 52-week low (0.7% of range)
Is BOT a buy right now?
Trend: BOT is trading below the 50-day average (-45.00%), RSI 13 — oversold territory, with a 3-month return of -45.00%.
Valuation & quality: Botanix Pharmaceuticals Limited trades on price-to-book 0.48; fundamentals show net margin -206.4%, return on equity -96.4%, revenue growth 219.6% year on year.
Analyst consensus: 3 analysts have a mean 12-month price target of A$0.48 (+4293.9% vs the last close; range A$0.14 – A$1.00), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Dermatology commercialization and regulatory execution provide a clearer path toward value creation.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -16.70% | -40.00% | -33.30% | +0.00% | +0.00% | +0.00% | +0.00% | -50.00% |
Fundamentals
Analyst price target
Technical signals
About Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.